Fig. 2
From: Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
Illustration of the canonical Hippo pathway and its dysregulation. MST1/2 and LATS1/2 are kinases. SAV1 (WW45) and MOB1A/B are adaptors. The phosphorylation cascade in the Hippo pathway can negatively regulate YAP/TAZ and inhibit the proliferation-promoting effects of YAP/TAZ. Dysregulation leads to proliferation, invasion, and migration of malignancies via the nuclear translocation of YAP and TAZ